{"product_id":"assertiotx-five-forces-analysis","title":"Assertio Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAssertio faces moderate competitive rivalry driven by niche specialty products, pricing pressure from larger pharma players, and steady buyer bargaining from PBMs and insurers; supplier influence is manageable but R\u0026amp;D costs and regulatory hurdles heighten entry barriers. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Assertio’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAssertio runs an asset-light model, relying almost entirely on contract manufacturing organizations (CMOs) for production; in 2024 about 95% of its product volumes came from third parties, heightening supplier power.\u003c\/p\u003e\n\u003cp\u003eAny CMO price rise or delay feeds straight into gross margin—Assertio reported a 2024 gross margin of ~58%, so a 5% CMO cost increase could cut margin by ~2.9 percentage points.\u003c\/p\u003e\n\u003cp\u003eThe small pool of CMOs that can make specialized neurology and pain drugs—roughly a dozen global sites—gives those suppliers outsized leverage over lead times and pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive Pharmaceutical Ingredient Source Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAssertio relies on few active pharmaceutical ingredient (API) suppliers for its core portfolio; in 2024 about 70% of key APIs came from two vendors, raising concentration risk.\u003c\/p\u003e\n\u003cp\u003eIf a primary API supplier hits FDA quality holds or a 30% production cut, Assertio could face 6–12 month sourcing delays given stringent approvals, squeezing output and revenue.\u003c\/p\u003e\n\u003cp\u003eThat supplier leverage lets vendors hold firm pricing; Assertio paid ~5–8% higher API costs in 2024 vs industry average, which slowed gross-margin recovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers with strong FDA compliance and specialty certifications wield significant power over Assertio, since switching active pharmaceutical ingredient (API) or contract manufacturing organizations (CMOs) triggers months-to-years of regulatory re-approval and can cost millions; a 2024 Parexel estimate puts average US drug CMC (chemistry, manufacturing, controls) changes at $2–5M and 6–18 months. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Packaging and Distribution Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCertain Assertio products need cold-chain logistics and specialized packaging to preserve efficacy; global cold-chain contract logistics capacity tightened after 2021, with premium rates up ~15–25% in 2024 according to Armstrong \u0026amp; Associates.\u003c\/p\u003e\n\u003cp\u003eFew niche providers control validated temperature-controlled packaging and GDP-compliant distribution, so Assertio’s growing specialty portfolio raises supplier leverage and can increase COGS and lead-time risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003cli\u003eSpecific reliance grows as specialty sales rise — 2024 specialty drugs = industry +8% YoY\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Industry Consolidation Among CMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIndustry consolidation among contract manufacturing organizations (CMOs) has cut the pool of independent partners by about 25% globally since 2018, leaving Assertio with fewer suppliers and weaker leverage.\u003c\/p\u003e\n\u003cp\u003eLarger CMOs now allocate capacity to high-volume clients: top 10 pharma customers account for roughly 60% of available commercial slots, sidelining smaller specialty firms like Assertio.\u003c\/p\u003e\n\u003cp\u003eResult: Assertio faces reduced bargaining power, higher per-unit COGS pressure (industry reports show 5–8% premium for small-batch runs) and lower priority for scarce production capacity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupplier pool down ~25% since 2018\u003c\/li\u003e\n\u003cli\u003eTop 10 clients take ~60% capacity\u003c\/li\u003e\n\u003cli\u003eSmall-batch premium +5–8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier concentration: 95% outsourced, 70% API from 2 vendors—margin \u0026amp; lead‑time risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAssertio’s supplier power is high: ~95% of production outsourced to CMOs in 2024, ~70% of key APIs from two vendors, and CMOs’ consolidation (~25% fewer since 2018) plus top-10 clients taking ~60% capacity raise costs and lead-time risk—2024 gross margin ~58% (a 5% CMO cost rise ≈ −2.9 pp). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO share\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI concentration\u003c\/td\u003e\n\u003ctd\u003e70% (2 vendors)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO pool change\u003c\/td\u003e\n\u003ctd\u003e−25% since 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Assertio, this Porter's Five Forces analysis uncovers key competitive drivers, supplier\/buyer power, substitution risks, and entry barriers—highlighting disruptive threats and strategic levers to protect market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces view tailored for Assertio—quickly spot competitive pressures and prioritize strategic moves to relieve margin and market-share stress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesaler Concentration and Market Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA vast majority of Assertio’s revenue flows through three US wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—who together account for roughly 60–70% of US pharmaceutical distribution; this concentration gives them strong leverage to demand deep discounts, rebates, and extended payment terms.\u003c\/p\u003e\n\u003cp\u003eThose wholesalers’ purchasing power compresses Assertio’s gross margins and forces higher working capital needs; for example, a 5–10% rebate demand could cut reported 2024 EBITDA by several million dollars.\u003c\/p\u003e\n\u003cp\u003eIf any one distributor shifts purchasing patterns or delists a product, Assertio would face immediate cash-flow stress given its reliance on these partners for most of its US net sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers and Formulary Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmacy Benefit Managers (PBMs) decide which drugs insurers cover and their copay tiers, so Assertio must negotiate hard to keep placement favorable; PBMs control over 80% of US prescription claims as of 2025, making their formulary decisions decisive.\u003c\/p\u003e\n\u003cp\u003eIf Assertio fails to secure preferred placement on a major PBM formulary, prescription volumes can drop sharply—studies show non-preferred placement can cut utilization by 30–70%. \u003c\/p\u003e\n\u003cp\u003eMaintaining rebate levels and patient access programs is essential to preserve market share and revenue, given Assertio’s small specialty portfolio and reliance on reimbursement pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Pricing and Reimbursement Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment payers (Medicare, Medicaid) cover a large share of Assertio’s US sales—Medicare Part D and Medicaid price rules pushed 2024 drug rebates above 20% industry-wide—so policy pushes for price transparency and caps let public programs demand lower net prices and bigger rebates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Provider Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe consolidation of independent clinics into large hospital systems has centralized purchasing; the top 50 US health systems now control about 40% of hospital beds (AHA 2024), raising buyers’ leverage to demand bulk pricing and favor generics.\u003c\/p\u003e\n\u003cp\u003eThese networks enforce standardized protocols and formularies, so Assertio must show clear clinical differentiation and cost-effectiveness to stay on system procurement lists and secure market share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop 50 systems ≈40% hospital beds (AHA 2024)\u003c\/li\u003e\n\u003cli\u003eBulk-contracting pushes generic preference\u003c\/li\u003e\n\u003cli\u003eNeed clinical outcomes + pharmacoeconomic data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Sensitivity to Out of Pocket Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cppatients facing high-deductible plans pay more oop and now favor generics in us hdhp enrollment hit of workers raising substitution risk for assertio when copays exceed by prompting pharmacists to swap brands.\u003e\u003cpto preserve access assertio must expand patient-assistance programs those discounts can cut net unit revenue by depending on program uptake and channel mix.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e31% US workers in HDHPs (2024)\u003c\/li\u003e\n\u003cli\u003eCopay gaps $20–$100 drive substitutions\u003c\/li\u003e\n\u003cli\u003ePAPs reduce net revenue 10–35%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pto\u003e\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated buyers, steep rebates \u0026amp; placement risk slash drug EBITDA and volumes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentrated U.S. wholesalers (AmerisourceBergen, Cardinal, McKesson) and PBMs (covering \u0026gt;80% claims) give buyers strong leverage, pressuring rebates and margins; a 5–10% rebate can cut 2024 EBITDA by millions and non-preferred PBM placement cuts volumes 30–70%. Public payers and hospital systems (top 50 ≈40% beds) further demand lower net prices; PAPs and HDHPs (31% workers, 2024) shift patients to generics, reducing net unit revenue 10–35%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler share\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM claim share (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHDHP enrollment (2024)\u003c\/td\u003e\n\u003ctd\u003e31%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebate impact\u003c\/td\u003e\n\u003ctd\u003e5–10% → millions off 2024 EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization loss (non-preferred)\u003c\/td\u003e\n\u003ctd\u003e30–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAP net revenue hit\u003c\/td\u003e\n\u003ctd\u003e10–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAssertio Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Assertio Porter’s Five Forces analysis you’ll receive after purchase—no placeholders or mockups, just the fully formatted document ready for immediate download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747460460921,"sku":"assertiotx-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/assertiotx-five-forces-analysis.png?v=1772198740","url":"https:\/\/growthsharematrix.com\/products\/assertiotx-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}